Hoffmann-La Roche: Multiple Sclerosis, Chronic Progressive trials
The registry lists 12 Multiple Sclerosis, Chronic Progressive studies with Hoffmann-La Roche as lead sponsor. 2 are open to participants now and 6 have results posted.
Phase 1 1Phase 2 2Phase 3 8Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyRecruitingNCT07609719Phase 4
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)RecruitingNCT07282574Phase 2
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple SclerosisCompletedNCT05232825Phase 3Results posted
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)Active, not recruitingNCT04548999Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisActive, not recruitingNCT04035005Phase 3Results posted
- Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)CompletedNCT02688985Phase 3Results posted
- A Study of Ocrelizumab in Participants With Primary Progressive Multiple SclerosisCompletedNCT01194570Phase 3Results posted
- A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple SclerosisCompletedNCT00087529Phase 2/3Results posted
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisActive, not recruitingNCT07667322Phase 1
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisActive, not recruitingNCT07483450Phase 4
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisActive, not recruitingNCT04544449Phase 3
- A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisActive, not recruitingNCT03523858Phase 3